Aminomethyl(Methyl)Phosphinic Acid

Aminomethyl(Methyl)Phosphinic Acid

SCHEMBL21271995

CCCCCCCCN.CP(=O)(O)CN

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 8/20 0.59
TSHR P16473 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
ALDH1A1 P00352 1/20 0.59
EPHX1 P07099 1/20 0.59
GABBR2 O75899 2/20 0.54
GABBR1 Q9UBS5 2/20 0.54
CYP1A2 P05177 1/20 0.54
THPO P40225 1/20 0.54
GABRR1 P24046 1/20 0.54
LMNA P02545 1/20 0.52
BLM P54132 1/20 0.52
SMPD1 P17405 2/20 0.50
FDPS P14324 1/20 0.50
LPAR2 Q9HBW0 1/20 0.48
LPAR3 Q9UBY5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21272149 1.00 DNM1 (0.59) DNM1TSHRMEN1KMT2AALDH1A1
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21272056 1.00 DNM1 (0.59) DNM1TSHRMEN1KMT2AALDH1A1
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21271939 0.91 GABBR2 (0.58) DNM1TSHRMEN1KMT2AALDH1A1
SCHEMBL21272021 0.91 DNM1 (0.65) DNM1TSHRMEN1KMT2AALDH1A1
Methyl Phosphonate SCHEMBL8008672 0.91 DNM1 (0.65) DNM1TSHRMEN1KMT2AALDH1A1
Octadecylamine SCHEMBL28212235 0.91 DNM1 (0.65) DNM1TSHRMEN1KMT2AALDH1A1
Dodecylamine SCHEMBL23525472 0.88 DNM1 (0.68) DNM1TSHRMEN1KMT2AALDH1A1
Phosphoric Acid SCHEMBL3406817 0.88 DNM1 (0.68) DNM1TSHRMEN1KMT2AALDH1A1
Phosphoric Acid SCHEMBL7118141 0.88 DNM1 (0.68) DNM1TSHRMEN1KMT2AALDH1A1
Octadecylamine SCHEMBL5885991 0.88 DNM1 (0.68) DNM1TSHRMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070856-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources SOILGENIC TECH LLC (US) 2026-03-12 US disclosed
US-12497344-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SOILGENIC TECHNOLOGIES, LLC (US) 2025-12-16 US disclosed
US-12139443-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SOILGENIC TECHNOLOGIES, LLC (US) 2024-11-12 US disclosed
US-20220242802-A1 CONCENTRATED LIQUID COMPOSITIONS OF UREASE INHIBITORS FOR NITROGEN SOURCES SOILGENIC TECHNOLOGIES, LLC 2022-08-04 US disclosed
US-20190256437-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources SOILGENIC TECHNOLOGIES, LLC 2019-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497344-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SRM, DNPH1, UROD DNM1 3988/4885TSHR 4220/4885MEN1 1879/4885
US-20260070856-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources PNP, UMPS, DNPH1 DNM1 4620/4885TSHR 2426/4885MEN1 3597/4885
US-20220242802-A1 CONCENTRATED LIQUID COMPOSITIONS OF UREASE INHIBITORS FOR NITROGEN SOURCES SRM, DNPH1, UROD DNM1 3988/4885TSHR 4220/4885MEN1 1879/4885
US-12139443-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SRM, DNPH1, UROD DNM1 3988/4885TSHR 4220/4885MEN1 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.